Amrize Forecast, price target & analysts
Amrize Target price 2025 - Analyst rating & recommendation
Amrize Classifications & Recommendation:
Amrize Price Target
| Target Price | $46.92 |
| Price | $55.75 |
| Deviation | 15.84% |
| Number of Estimates | 12 |
| 12 Analysts have issued a price target Amrize 2026 . The average Amrize target price is $46.92. This is 15.84% lower than the current stock price. The highest price target is $53.55 3.95% , the lowest is $34.20 38.65% . | |
| A rating was issued by 16 analysts: 11 Analysts recommend Amrize to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Amrize stock has an average upside potential 2026 of 15.84% . Most analysts recommend the Amrize stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 11.70 | 12.09 |
| 0.23% | 3.30% | |
| EBITDA Margin | 25.76% | 25.44% |
| 10.51% | 1.24% | |
| Net Margin | 10.89% | 10.92% |
| 32.96% | 0.32% |
13 Analysts have issued a sales forecast Amrize 2025 . The average Amrize sales estimate is $12.1b . This is 34.69% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $12.6b 40.36% , the lowest is $11.3b 26.24% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $11.7b | 0.23% |
|---|---|---|
| 2025 | $12.1b | 3.30% |
| 2026 | $12.6b | 4.26% |
| 2027 | $13.3b | 5.76% |
| 2028 | $14.1b | 5.42% |
| 2029 | $15.0b | 6.72% |
| 2030 | $15.4b | 2.88% |
| 2031 | $16.5b | 6.75% |
| 2032 | $17.3b | 4.77% |
12 Analysts have issued an Amrize EBITDA forecast 2025. The average Amrize EBITDA estimate is $3.1b . This is 85.52% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.3b 97.29% , the lowest is $2.8b 70.51% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $3.0b | 10.76% |
|---|---|---|
| 2025 | $3.1b | 2.02% |
| 2026 | $3.3b | 6.96% |
| 2027 | $3.6b | 8.97% |
| 2028 | $3.9b | 9.15% |
| 2029 | $4.2b | 7.62% |
| 2030 | $4.4b | 3.89% |
| 2031 | $4.9b | 12.09% |
| 2032 | $5.1b | 4.26% |
EBITDA Margin
| 2024 | 25.76% | 10.51% |
|---|---|---|
| 2025 | 25.44% | 1.24% |
| 2026 | 26.10% | 2.59% |
| 2027 | 26.89% | 3.03% |
| 2028 | 27.84% | 3.53% |
| 2029 | 28.08% | 0.86% |
| 2030 | 28.36% | 1.00% |
| 2031 | 29.77% | 4.97% |
| 2032 | 29.63% | 0.47% |
13 Amrize Analysts have issued a net profit forecast 2025. The average Amrize net profit estimate is $1.3b . This is 48.88% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $1.6b 77.43% , the lowest is $1.1b 29.55% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $1.3b | 33.26% |
|---|---|---|
| 2025 | $1.3b | 3.66% |
| 2026 | $1.5b | 14.60% |
| 2027 | $1.7b | 15.27% |
| 2028 | $1.9b | 7.08% |
| 2029 | $2.2b | 18.38% |
| 2030 | $2.4b | 7.40% |
| 2031 | $2.6b | 8.08% |
| 2032 | $2.7b | 5.49% |
Net Margin
| 2024 | 10.89% | 32.96% |
|---|---|---|
| 2025 | 10.92% | 0.32% |
| 2026 | 12.01% | 9.98% |
| 2027 | 13.09% | 8.99% |
| 2028 | 13.29% | 1.53% |
| 2029 | 14.75% | 10.99% |
| 2030 | 15.39% | 4.34% |
| 2031 | 15.58% | 1.23% |
| 2032 | 15.69% | 0.71% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.30 | 2.39 |
| 32.95% | 3.91% | |
| P/E | 23.35 | |
| EV/Sales | 3.00 |
13 Analysts have issued a Amrize forecast for earnings per share. The average Amrize EPS is $2.39 . This is 49.38% higher than earnings per share in the financial year 2024. The highest EPS forecast is $2.85 78.13% , the lowest is $2.08 30.00% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $2.30 | 32.95% |
|---|---|---|
| 2025 | $2.39 | 3.91% |
| 2026 | $2.74 | 14.64% |
| 2027 | $3.15 | 14.96% |
| 2028 | $3.38 | 7.30% |
| 2029 | $4.00 | 18.34% |
| 2030 | $4.29 | 7.25% |
| 2031 | $4.64 | 8.16% |
| 2032 | $4.90 | 5.60% |
P/E ratio
| Current | ||
|---|---|---|
| 2025 | 23.35 | 32.99% |
| 2026 | 20.37 | 12.76% |
| 2027 | 17.68 | 13.21% |
| 2028 | 16.51 | 6.62% |
| 2029 | 13.94 | 15.57% |
| 2030 | 12.98 | 6.89% |
| 2031 | 12.01 | 7.47% |
| 2032 | 11.39 | 5.16% |
Based on analysts' sales estimates for 2025, the Amrize stock is valued at an EV/Sales of 3.00 and an P/S ratio of 2.55 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.04 | |
|---|---|---|
| 2025 | 3.00 | 25.69% |
| 2026 | 2.88 | 4.08% |
| 2027 | 2.72 | 5.45% |
| 2028 | 2.58 | 5.14% |
| 2029 | 2.42 | 6.30% |
| 2030 | 2.35 | 2.80% |
| 2031 | 2.20 | 6.33% |
| 2032 | 2.10 | 4.56% |
P/S ratio
| Current | ||
|---|---|---|
| 2025 | 2.55 | 25.76% |
| 2026 | 2.45 | 4.09% |
| 2027 | 2.32 | 5.44% |
| 2028 | 2.20 | 5.14% |
| 2029 | 2.06 | 6.29% |
| 2030 | 2.00 | 2.80% |
| 2031 | 1.87 | 6.33% |
| 2032 | 1.79 | 4.55% |
Current Amrize Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Dec 08 2025 |
| Stephens & Co. |
➜
Overweight
|
Initiated | Nov 14 2025 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Nov 03 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Nov 03 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Oct 30 2025 |
| Citigroup |
➜
Buy
|
Initiated | Oct 17 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Oct 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Dec 08 2025 |
|
Initiated
Stephens & Co.:
➜
Overweight
|
Nov 14 2025 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Nov 03 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Nov 03 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Oct 30 2025 |
|
Initiated
Citigroup:
➜
Buy
|
Oct 17 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Oct 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
